CLAIMS

What is claimed is:

1. A drug-molecule conjugate comprising a drug and a molecule which binds to a CAR expressed on the surface of a cell.

2. The conjugate of claim 1, wherein binding of the conjugate to the CAR results in internalization of the conjugate into the cell.

3. The conjugate of claim 1, wherein binding of the conjugate to the CAR results in the drug-mediated death of the cell.

4. The conjugate of claim 1, wherein the cell is a T cell and wherein binding of the conjugate to the CAR results in the drug-mediated inhibition of the activation of the T cell.

5. The conjugate of claim 1, wherein the molecule is selected from the group consisting of an antibody, a protein, a peptide, a nucleotide, a small molecule, and fragments thereof.

6. A method for inhibiting the depletion of healthy tissue during CAR T cell therapy comprising administering a drug-molecule conjugate comprising a drug and a molecule to a subject receiving CAR T cell therapy, wherein the molecule binds to a CAR expressed on the surface of a T cell.

7. The method of claim 6, wherein binding of the conjugate to the CAR results in internalization of the conjugate into the cell.

8. The method of claim 6, wherein the binding of the conjugate to the CAR results in the drug-mediated death of the cell.

9. The method of claim 6, wherein the binding of the conjugate to the CAR results in the drug-mediated inhibition of the activation of the T cell.

10. The method of claim 6, wherein the molecule is selected from the group consisting of an antibody, a protein, a peptide, a nucleotide, a small molecule, and fragments thereof.

CLAIMS

What is claimed is:

1. A drug-molecule conjugate comprising a drug and a molecule which binds to a CAR expressed on the surface of a cell.

2. The conjugate of claim 1, wherein binding of the conjugate to the CAR results in internalization of the conjugate into the cell.

3. The conjugate of claim 1, wherein binding of the conjugate to the CAR results in the drug-mediated death of the cell.

4. The conjugate of claim 1, wherein the cell is a T cell and wherein binding of the conjugate to the CAR results in the drug-mediated inhibition of the activation of the T cell.

5. The conjugate of claim 1, wherein the molecule is selected from the group consisting of an antibody, a protein, a peptide, a nucleotide, a small molecule, and fragments thereof.

6. A drug-molecule conjugate for use as a medicament for inhibiting the depletion of healthy tissue during CAR T cell therapy comprising a drug and a molecule to a subject receiving CAR T cell therapy, wherein the molecule binds to a CAR expressed on the surface of a T cell.

7. The conjugate of claim 6, wherein binding of the conjugate to the CAR results in internalization of the conjugate into the cell.

8. The conjugate of claim 6, wherein the binding of the conjugate to the CAR results in the drug-mediated death of the cell.

9. The conjugate of claim 6, wherein the binding of the conjugate to the CAR results in the drug-mediated inhibition of the activation of the T cell.

10. The conjugate of claim 6, wherein the molecule is selected from the group consisting of an antibody, a protein, a peptide, a nucleotide, a small molecule, and fragments thereof.